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Abstract
Background: Pneumonia remains the leading cause of death in young children globally and improved diagnostics are
needed to better identify cases and reduce case fatality. Metabolomics, a rapidly evolving field aimed at characterizing
metabolites in biofluids, has the potential to improve diagnostics in a range of diseases. The objective of this pilot study is
to apply metabolomic analysis to childhood pneumonia to explore its potential to improve pneumonia diagnosis in a high-
burden setting.
Methodology/Principal Findings: Eleven children with World Health Organization (WHO)-defined severe pneumonia of
non-homogeneous aetiology were selected in The Gambia, West Africa, along with community controls. Metabolomic
analysis of matched plasma and urine samples was undertaken using Ultra Performance Liquid Chromatography (UPLC)
coupled to Time-of-Flight Mass Spectrometry (TOFMS). Biomarker extraction was done using SIMCA-P
+ and Random Forests
(RF). ‘Unsupervised’ (blinded) data were analyzed by Principal Component Analysis (PCA), while ‘supervised’ (unblinded)
analysis was by Partial Least Squares-Discriminant Analysis (PLS-DA) and Orthogonal Projection to Latent Structures (OPLS).
Potential markers were extracted from S-plots constructed following analysis with OPLS, and markers were chosen based on
their contribution to the variation and correlation within the data set. The dataset was additionally analyzed with the
machine-learning algorithm RF in order to address issues of model overfitting and markers were selected based on their
variable importance ranking. Unsupervised PCA analysis revealed good separation of pneumonia and control groups, with
even clearer separation of the groups with PLS-DA and OPLS analysis. Statistically significant differences (p,0.05) between
groups were seen with the following metabolites: uric acid, hypoxanthine and glutamic acid were higher in plasma from
cases, while L-tryptophan and adenosine-59-diphosphate (ADP) were lower; uric acid and L-histidine were lower in urine
from cases. The key limitation of this study is its small size.
Conclusions/Significance: Metabolomic analysis clearly distinguished severe pneumonia patients from community controls.
The metabolites identified are important for the host response to infection through antioxidant, inflammatory and
antimicrobial pathways, and energy metabolism. Larger studies are needed to determine whether these findings are
pneumonia-specific and to distinguish organism-specific responses. Metabolomics has considerable potential to improve
diagnostics for childhood pneumonia.
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Introduction
Pneumonia is the biggest single cause of death in children,
accounting for around 20% of 10 million deaths under the age of 5
years every year globally, 70% of these occurring in sub-Saharan
Africa [1–8]. In The Gambia acute lower respiratory infection
(ALRI), principally pneumonia, has been documented as the
leading cause of death in young children [9,10]. The global
burden of death from pneumonia will need to be markedly
reduced if there is to be any prospect of achieving the United
Nations’ Millennium Development Goal 4 (MDG-4), that is, the
reduction of under-5 mortality two-thirds by the year 2015
[11,12]. International momentum is building to meet this
challenge [13].
Case management will remain a key strategy in reducing the
mortality of pneumonia, and other infectious diseases, even if
current vaccines fulfill their promise. Better diagnostics will be
needed to improve case management, the more so as the
introduction of conjugate vaccines worldwide changes the
aetiology and epidemiology of pneumonia [14,15]. New labora-
tory approaches have the potential to deliver improvements in
diagnostics and metabolomic analysis is one of these.
Metabolomics is a rapidly evolving field that aims to identify
and quantify the concentration changes of all the metabolites (i.e.,
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12655the metabolome) in a biofluid (e.g. blood, saliva, urine) or model
system. This approach has been used successfully to identify
biomarkers following exposure to ionizing radiation [16–19],
metastatic prostate cancer [20–23] and assess differences in gut
microbiota [24–27]. Additionally, it has been utilized to identify
biomarkers through Nuclear Magnetic Resonance (NMR) in
primarily adult onset pneumonia with known causative agents
[28–30] and in further elucidation of metabolic pathways of lung
injury in mice [31,32]. Metabolomics has the potential to both
improve the understanding of disease mechanisms and the
diagnostics. It can be applied to easily accessible biofluids and
may offer the eventual possibility of effective non-invasive bedside
testing.
This paper describes the application of metabolomic methods in
a pilot study to characterize children with and without severe
pneumonia. The objective is to obtain preliminary data to assess
whether metabolomic analysis might be able to distinguish these
groups and hence have potential diagnostic application. It is also
hoped that this data might provide pointers for the future
exploration of disease mechanisms in childhood pneumonia.
Methods
Study Setting, Design, Patient Selection, Consent and
Ethical Approval
The Gambia is a geographically long and narrow sub-Saharan
African country, extending 400 km inland from the West African
coast along the Gambia River. It has a population of 1.4 million,
over 40% of which is less than 15 years of age (2003 census) [33].
A study of the aetiology of childhood pneumonia is being
undertaken in the coastal area of The Gambia (Fig. 1), in which
cases of pneumonia are being enrolled along with community
controls. The study area comprises Banjul, Kanifing, and Kombo
(North, South, Central and East) municipalities. Written informed
consent from the parent or guardian is required for inclusion in the
study. Specific written informed consent is obtained for percuta-
neous lung aspiration where the procedure is indicated. The study
was approved by the Gambia Government-Medical Research
Council Joint Ethics Committee (L2008.28).
Entry Criteria and Case Definitions
Cases are children aged between 2 and 59 months, originating
from within the study area, presenting to the Medical Research
Council (MRC) hospital in Fajara, the Royal Victoria Teaching
Hospital in Banjul (RVTH), Fajikunda Health Centre, Serekunda
Health Centre, or Brikama Health Centre with severe or very
severe pneumonia defined clinically by modified World Health
Organization (WHO) criteria. Severe pneumonia is defined as
cough or difficulty breathing, plus any of lower chest wall
indrawing, nasal flaring, or an oxygen saturation of ,90% on
pulse oximetry (the latter defining very severe pneumonia).
Children with a cough of two or more weeks, those with severe
anemia (Hb ,6 g/dL) and those with confirmed wheeze at
recruitment are excluded. Community controls without WHO-
defined pneumonia, matched by neighborhood age and sex, are
recruited for cases in a 1:1 ratio.
Sample Collection, Selection, and Microbiology
Blood from cases was collected for culture and a full blood
count, and urine was collected where practicable. Percutaneous
lung aspiration for culture was performed where defined safety
criteria were met and written informed consent was given. Blood
and lung aspirate samples were also subjected to molecular
analysis for pathogen detection using Streptococcus pneumoniae and
Haemophilus influenzae specific primers (lytA and cpsA for S.
pneumoniae, glpQ for H. influenzae) and 16SrRNA primers with
sequencing of the gel electrophoresis bands for identification of
other bacterial species. The culture and molecular methods used
Figure 1. Map of The Gambia, showing hospitals and major health centres and the coastal region in which the study was
conducted.
doi:10.1371/journal.pone.0012655.g001
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one hundred fifteen severe cases had been enrolled in the study of
which complete verified data were available for ninety three. Of
these, eleven severe pneumonia cases and matched community
controls were available that had both plasma and urine samples of
sufficient volume for analysis and these were selected for this pilot
study. The samples were stored at 240uC and aliquots were
shipped on dry ice to Georgetown University for metabolomic
analysis.
Sample Analysis
Urine and plasma samples were analyzed using Ultra
Performance Liquid Chromatography (UPLC) coupled to Time-
of-Flight Mass Spectrometry (TOFMS) from Waters (Milford,
MA). In particular, urine samples were deproteinized by 1:5
dilution in 50% acetonitrile with 2 mM debrisoquine sulfate and
30 mM 4-nitrobenzoic acid as internal controls. Plasma samples
were deproteinized by 1:40 dilution in 66% acetonitrile containing
2 mM debrisoquine sulfate and 30 mM 4-nitrobenzoic acid as
internal controls. Following centrifugation at 13,0006g, 5 mL of
the supernatant were injected into the UPLC-TOFMS. A Waters
Acquity UPLC BEH C18 2.1650 mm column packed with
1.7 mm beads was used to separate the molecules in the biofluids
set at 40uC for the urine and 60uC for plasma. The mobile phase
flow rate was set at 0.5 mL/min. The gradient mobile phase
consisted of water with 0.1% formic acid (A) and acetonitrile
containing 0.1% formic acid (B). A 10 min urine sample run
consisted of 0.5 min of 99% (A), 3.5 min of 20% (B), 4 min of 95%
(B), 1 min of 99% (B), and finally 1 min of 99% (A). A 10 min
plasma sample run consisted of 0.5 min of 100% of (A), 3.5 min of
60% of (B), 5 min of 100% of (B), and finally 1 min of 100% of (A).
Mass spectrometry and accurate mass acquisition was performed
with a Waters QTOF PremierH (Milford, MA) operating at either
positive-ion (ESI+) or negative-ion (ESI-) electrospray ionization
mode. The capillary voltage was set to 3200 V and the sampling
cone voltage to 45 V. The desolvation gas flow was set to 800 L/h
and the temperature was set to 350uC. The cone gas flow was set
to 25 L/h for plasma and 15 L/h for urine and the temperature
was set to 130uC. Intermittent injections of sulfadimethoxine as a
lock mass ([M+H]
+=311.0814 m/z and [M2H]
2=309.0658
m/z) at a concentration of 300 pg/mL in 50% acetonitrile at a
rate of 40 mL/min, were used for accurate mass measurements.
Data Processing and Multivariate Data Analysis
Mass chromatograms and spectra were acquired with the
software MassLynx (Waters) in centroid format and markers were
extracted with the software MarkerLynx (Waters). Urine samples
were normalized to their respective creatinine relative peak area of
[M+H]
+=114.0667 m/z with retention time of 0.32 min before
further analysis of the data. Two separate multivariate statistical
methods were utilized for biomarker extraction, SIMCA-P
+ vs
12.0 (Umetrics, Sweden) and the machine-learning algorithm
Random Forests (RF). For SIMCA-P
+ analysis, all centroid data
were Pareto scaled, which increases the importance of low
abundance ions without giving importance to noise. ‘Unsuper-
vised’ (i.e. blinded, identity of the samples was not known by the
Georgetown group) data were analyzed by Principal Component
Analysis (PCA), while ‘supervised’ (i.e. unblinded, identity of the
samples was later revealed) analysis was by Partial Least Squares-
Discriminant Analysis (PLS-DA) and Orthogonal Projection to
Latent Structures (OPLS). Potential markers were extracted from
S-plots constructed following analysis with OPLS, and markers
were chosen based on their contribution to the variation and
correlation within the data set.
In order to address issues concerning overfitting of the data,
which is common with large datasets containing relatively small
numbers of samples, Random Forests analysis was performed
through R, a programming language that allows for statistical
processing [37]. Random Forests is a machine-learning algorithm
that has been used successfully in identifying metabolic biomarkers
in biofluids [16,19,38]. The samples were assigned to control
versus pneumonia groups and ten thousand trees were constructed
with variable importances averaged over twenty five independent
random forests. Multidimensional scaling plots were constructed
with analysis of either the whole sample set or the top one hundred
metabolites and percentages of classification accuracy were
calculated. Bootstrapping of the results from the twenty five
independent random trees was applied to determine the 95%
confidence intervals of the variable importance ranks. Addition-
ally, heatmaps were designed of the top fifty ions generated
through RF. The samples were grouped by treatment and the
metabolites were hierarchically clustered by complete linkage
using the euclidian distance. To aid in visualization, each
metabolite was scaled by the maximum intensity value of that
metabolite in the data set (i.e. each row was divided by the
maximum value in the row before color assignment).
Molecular Ion Identification
Selected ions that showed variable differences between the
Control and Pneumonia groups were chosen for further analysis
and identification. Fifteen ions from either urine or plasma samples
were chosen based on the S-plot and RF significance ranking and
exhibited statistically significant p-values (p,0.05) based on analysis
of the means of the data through two-tailed t-test. Searches for the
identity of the metabolites were conducted through the publicly
available online database ‘‘Madison Metabolomics Consortium
Database’’ (MMCD) with tol (ppm) equal to twenty and ions were
validated through tandem mass spectrometry (MS/MS) against
pure chemicals (Sigma Aldrich, St. Louis, MO). Chemicals of the
highest available purity were either diluted in 50% acetonitrile for
urine samples or 66% acetonitrile for plasma samples and
fragmented with ramping collision energy of 5–30 eV. MS/MS
spectra of the pure chemicals were compared to the biological
sample MS/MS spectra for the masses in question.
Results
Among the eleven children with clinically defined severe
pneumonia (the cases), five were female and six were male, and
six of the eleven were under two years old while five were two years
or older. Ten had radiographic changes of pneumonia, while the
other had a normal radiograph. The length of illness at presentation
ranged from 1–7 days (median 3 days) and four children had
reportedly received antibiotics before presentation. The total white
blood count of cases ranged from 7.8 to 67.7610
3/mm
3 (median
13.4) compared to 3.9–11.0 (median 7.2) in community controls.
Culture of blood (n=11) or lung aspirate (n=3) identified a
pathogen in just one case (S. pneumoniae) and blood cultures were
negative in all controls. Molecular analyses of plasma and lung
aspirate identified an organism in seven out of eleven cases: S.
pneumoniae in five, H. influenzae in one and S. pneumoniae and H.
influenzae in the other. Five of the eleven asymptomatic community
controls also had organisms identified (S. pneumoniae in one, H.
influenzae in three, S. pneumoniae and H. influenzae in one).
Multivariate Data Analysis of Urine Samples
The urine samples were analyzed in both positive and
negative ionization modes with the UPLS-TOFMS. Unsuper-
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when investigating the first two principal components for the
results of positive ionization mode (Fig. 2A). However, a clearer
separation of the groups for the negative mode data was seen
when the samples were analyzed with PLS-DA (Fig. S1).
Additionally, OPLS showed good clustering of the control and
pneumonia groups, with larger variation in the pneumonia
group (Fig. S1). The S-plots that were constructed from the
OPLS analysis showed a significant number of ions up-regulated
in the pneumonia group. Additionally, the supervised PLS-DA
analysis with assignment of the groups based on disease status
and sex revealed a sex dependent clustering of the pneumonia
group, which was not present in the controls (Fig. S3). Similar
analysis based on age or antibiotic usage within seven days of
sample collection did not reveal any clear clustering (data not
shown).
RF analysis, utilizing the whole sample set of ions, showed
distinct clustering of the two groups in positive mode; however,
three of the pneumonia samples were misclassified as belonging in
the control group. The overall classification accuracy of the sample
set was 86.4%. The negative mode data had an overall
classification accuracy of 95.5%, with only one sample of the
pneumonia group misclassified as belonging in the controls. A
heatmap was additionally constructed based on the top fifty
ranked metabolites of the positive mode data, revealing patterns of
differential levels of urinary metabolites between controls and
pneumonia samples (Fig. 2E).
Ion selection for verification was based either on the abundance
and correlation coordinates of the ions on the S-plot or the
importance ranking from RF. Specifically, seven urinary ions were
picked based on these criteria for further analysis. Of those, the
identity of two ions was verified through MS/MS. Ion 1 from
Table 1 with [M+H]
+=169.0352 m/z and retention time of
0.3281 min was identified as uric acid, which is involved in the
metabolism of purines (Fig. 3A, p=0.026). Ion 2 with
[M+Na]
+=178.0586 m/z and retention time of 0.2729 min was
verified as L-histidine (Fig. 3B, p=0.004). Additional search for
the protonated form of L-histidine revealed an ion at
[M+H]
+=156.078 m/z and retention time of 0.2864 min
(Fig. 3C, p=0.00196).
Five additional urinary ions were further evaluated with MS/
MS, though the identities were not verified against the pure
chemicals that were tested. In particular ion number 8
([M2H]
2=145.0606 m/z, retention time of 2.764 min), ion
number 9 ([M+H]
+=101.0356 m/z, retention time of
0.2948 min), ion number 10 ([M+H]
+=335.0676 m/z, retention
time of 2.3983 min), ion number 11 ([M+H]
+=241.0326 m/z,
retention time of 3.9999 min), and ion number 12
([M+H]
+=243.0986 m/z, retention time of 0.3166 min) were
tested against L-glutamine, alanyl-glycine (Ala-Gly), adipic acid,
and D-glutamine for ion 8, hydantoin for ion 9, b-nicotinamide
mononucleotide for ion 10, L-cystine for ion 11, and b-thymidine
for ion 12. Ions 3–7 and 15 (Table 1) have been clearly marked on
Fig. 2D and 2F.
Multivariate Data Analysis of Plasma Samples
The plasma samples were also analyzed in both positive and
negative ionization modes. No normalization was applied to the
samples, unlike the urines, since the levels of the plasma that were
obtained were tightly controlled. Analysis of the positive ionization
mode data with the multivariate statistical software SIMCA-P
+
demonstrated a good separation between the two groups at the
PCA scores plot (Fig. S2). Only one sample of the control group
was misclassified as belonging in the pneumonia group, meaning
that its overall metabolite profile resembled closely that of the
pneumonia group. The separation became clearer when super-
vised PLS-DA analysis was applied, demonstrating the variable
differences between the two groups (Fig. S2). On the negative
ionization mode, the PCA analysis also revealed a clear separation
between the two experimental groups, with only one pneumonia
sample being misclassified as belonging in the control group
(Fig. 2B). Furthermore, the PLS-DA and OPLS scores plots
revealed a distinct separation of controls from pneumonia samples
(Fig. S2). For further analysis of ions, the negative mode S-plot was
chosen for extraction of markers (Fig. 2D). RF analysis showed an
overall classification accuracy of 86.4%, which increased to 90.9%
when only the top one hundred ions were used to classify the
samples into separate groups. The percentages of classification
accuracy were identical for the analysis of both positive and
negative mode data.
Selected ions for further verification and validation were chosen
through the S-plots and RF top ranked lists. In particular, ion
number 3 with [M2H]
2=167.0202 m/z, retention time of
0.3179 min was verified as uric acid, which as mentioned earlier
is involved in the purine metabolism. Plasma levels of uric acid
appear to be upregulated in the pneumonia group relative to the
controls, although not statistically significant (Fig. 4A, p=0.119).
This is in contrast to the urine levels where the uric acid levels are
downregulated in the pneumonia group (Fig. 3A, p=0.026). Ion
number 4 with [M2H]
2=135.0303 m/z, retention time of
0.3158 min was verified to be hypoxanthine, also involved in the
metabolism of purines (Fig. 4B, p=0.008). Ion number 5 with
[M2H]
2=146.0447 m/z, retention time of 0.2821 min was
verified to be glutamic acid, involved in multiple metabolic
processes (Fig. 4C, p=0.0165). Ion number 6 with
[M2H]
2=203.0811 m/z, retention time of 1.6051 min was
verified to be L-tryptophan, which is an essential amino acid
and the only stereoisomer used in structural or enzymatic proteins
(Fig. 4D, p=0.006). Ion number 7 with [M2H]
2=426.0235 m/z
and retention time of 0.3533 min was verified to be adenosine-59-
diphosphate (ADP) (Fig. 4E, p=0.0004).
Four additional ions were further investigated with MS/MS
againstpurechemicals;however,theiridentitywasnotverifiedasthe
MS/MS spectra differed significantly. In particular ion number 13
([M+H]
+=274.0924 m/z, retention time of 0.317 min), ion number
14([M+H]
+=112.0496 m/z, retention time of0.3231 min), and ion
number 15 ([M2H]
2=145.0604 m/z, retention time of 0.273 min)
were tested against 29-deoxyadenosine and muramic acid for ion 13,
cytosine and pyrrole-2-carboxylic acid for ion 14, and L-glutamine,
Ala-Gly, adipic acid, and D-glutamine for ion 15. Ions 3–6, 14 and
15 (Table 1) have clearly been marked on both the S-plot and the
heatmap (Fig. 4D and F).
Discussion
Metabolomics is a powerful new technology that allows for the
assessment of global metabolic profiles in easily accessible biofluids
and biomarker discovery in order to distinguish between diseased
and non-diseased status. We utilized this approach in a pilot study
in urine and plasma samples from pneumonia patients from The
Gambia. The global metabolic profiling and subsequent multi-
variate analysis clearly distinguished severe pneumonia patients
from matched community controls. Although no common
pathogenic factor was identified in all the cases, it is noteworthy
that a similar disease manifestation allows for similar metabolic
profiles and identification of biomarkers. Six metabolites emerged
as markers of key differences between the two groups: uric acid, L-
histidine, hypoxanthine, glutamic acid, L-tryptophan, and ADP.
Child Pneumonia Metabolomics
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+ and Random Forests revealed differences in ion
abundance between the two groups. Panels A and B show PCA scores plots for urine (ESI+ mode) and for plasma (ESI - mode), respectively. PCA
analysis is an unsupervised method of extracting information, where the classes (i.e. experimental groups) are unknown. Panels C and D show the S-
plots constructed from the supervised OPLS analysis of urine (ESI+ mode) and plasma (ESI- mode) respectively. Ions with the highest abundance and
correlation in the pneumonia group with respect to the controls are present on the upper far right hand quadrant, whereas ions with the lowest
abundance and correlation in the pneumonia group with respect to the control group are residing in the lower far left hand quadrant. Ions are
marked with either their identity or a number corresponding to Table 1. Panels E and F show heatmaps for urine (ESI+ mode) and plasma (ESI- mode)
respectively. The heatmaps were constructed based on the top fifty metabolites of importance, which were extracted with Random Forests analysis.
Variable differences are revealed between the control and pneumonia groups, with verified and unknown ions marked on the right corresponding to
Table 1. The parallel analysis of the samples with SIMCA-P
+ and Random Forests allows for the ability to verify that ions, which are identified through
both ways (i.e. hypoxanthine), are highly significant, as depicted through two completely different algorithms. Additionally, it allows for the increase
of the numbers of ions that are potential candidates for biomarkers.
doi:10.1371/journal.pone.0012655.g002
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infection through antioxidant, inflammatory and antimicrobial
pathways, and energy metabolism.
Our observation of lower levels of urinary uric acid in severe
pneumonia patients relative to controls suggests increased tubular
reabsorption and renal retention of the analyte perhaps to protect
Figure 3. Relative changes of urinary ions that were verified with tandem mass spectrometry. Data is represented at the mean 6 SE of
the peak areas extracted through the TOFMS data (with * representing p,0.05 and ** representing p,0.01). The real peak areas were normalized to
each sample’s respective creatinine ([M+H]
+=114.0667 m/z) peak area.
doi:10.1371/journal.pone.0012655.g003
Table 1. Identification of urinary and plasma biomarkers in severe pneumonia cases.
Mass (m/z)
Marker No.
Retention
Time (min) ESI Mode Biofluid Found Calculated
ppm
error Empirical formula Identity
Relative to
Controls
1 0.3281 pos Urine 169.0352 169.0361 5.3 C5H4N4O3 Uric Acid Decreased
2 0.2729 pos Urine 178.0586 178.0592 3.4 C6H9N3O2 L-Histidine+Na Decreased
2b 0.2864 pos Urine 156.078 156.0772 5.1 C6H9N3O2 L-Histidine Decreased
3 0.3179 neg Plasma 167.0202 167.0205 1.8 C5H4N4O3 Uric Acid Increased
4 0.3158 neg Plasma 135.0303 135.0307 3.0 C5H4N4O Hypoxanthine Increased
5 0.2821 neg Plasma 146.0447 146.0453 4.1 C5H8NO4
2 Glutamic Acid Increased
6 1.6051 neg Plasma 203.0811 203.0820 4.4 C11H12N2O2 L-Tryptophan Decreased
7 0.3533 neg Plasma 426.0235 426.0216 4.5 C10H15N5O10P2 ADP Decreased
8 2.764 neg Urine - - - - Unknown -
9 0.2948 pos Urine - - - - Unknown -
10 2.3983 pos Urine - - - - Unknown -
11 3.9999 pos Urine - - - - Unknown -
12 0.3166 pos Urine - - - - Unknown -
13 0.317 pos Plasma - - - - Unknown -
14 0.3231 pos Plasma - - - - Unknown -
15 0.273 neg Plasma - - - - Unknown -
Biomarkers that exhibit significant differences between controls and pneumonia samples as determined through SIMCA-P
+ and Random Forests. Markers 1–7 have been
verified through tandem mass spectrometry (MS/MS) against pure chemical standards. Markers 8–15, although were determined as of high importance through the
multivariate data analysis, were also tested against pure chemical standards, but were not verified as such.
doi:10.1371/journal.pone.0012655.t001
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acid were elevated in pneumonia cases. In in vitro studies, uric acid
reacted rapidly with ozone and conferred protection of plasma
lipids from peroxidation and erythrocyte lysis [39]. Additional
studies have shown that uric acid released from injured cells
constitutes a major endogenous danger signal that activates the
NALP3 inflammasome (also called cryopyrin or NLRP3), leading
to IL-1b production [41] as part of the host response to lung
inflammation and fibrosis. Taken together, these studies suggest
that uric acid plays a major anti-inflammatory role in pneumonia
cases and allows for protection of the host organism from oxidative
damage. Additionally, plasma hypoxanthine levels were elevated
in patients relative to controls. Hypoxanthine and xanthine are the
precursors of uric acid and uric acid was also elevated in the
plasma of pneumonia patients, although not statistically signifi-
cant. Xanthine on the other hand was not identified as a marker
through the statistical analysis. High concentrations of hypoxan-
thine, xanthine, and uric acid have also been shown in patients
with bacterial meningitis [42]. This may be because sepsis
provokes significant alterations in energy metabolism homeostasis
with hypoxanthine and uric acid, offering possibly useful surrogate
markers of infection [42,43]. Elevation of hypoxanthine has also
been reported during septic shock and may reflect early high
energy nucleotide failure [44].
An additional marker with potentially important implications
for disease outcome is ADP. The main role of ADP in the blood is
the activation of platelets for effective hemostasis and blood
aggregation [45,46]. Our results indicated that ADP levels in
plasma from pneumonia patients are downregulated. This in turn
may lead to decreased platelet activation and decreased formation
of aggregates and thromboemboli. Lack of purinergic receptors for
ADP is a possible way to protect against aggregate formation,
however the reduced plasma levels of ADP in pneumonia patients
in our studies could confer a protective mechanism against organ
failure [45,47]. Nonetheless, other mechanisms, such as chemo-
kine activation [46], appear to mediate the platelet activation
under certain conditions, such as low ADP availability. Further
work is required in this direction of low plasma ADP in
pneumonia cases and its role in disease outcome and patient
survival.
The last three markers identified in this study are amino acids.
Hendriksen et al stressed that glutamic acid uptake and synthesis is
Figure 4. Relative changes of the plasma ions that were verified with tandem mass spectrometry. Data is represented as mean 6 SE of
the peak areas extracted through the TOFMS data (with * representing p,0.05 and ** representing p,0.01). Unlike the urine samples, plasma
samples do not require normalization to a particular metabolite since the volumes obtained are tightly controlled. Uric acid (Panel A) is upregulated
in pneumonia plasma levels, although not statistically significant (p=0.119). This is in contrast to the urine findings. Hypoxanthine and glutamic acid
levels in Panels B and C are significantly upregulated in pneumonia samples. On the other hand, L-tryptophan and adenosine-59-diphosphate (ADP)
in Panels D and E are significantly downregulated in pneumonia samples.
doi:10.1371/journal.pone.0012655.g004
Child Pneumonia Metabolomics
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12655important for full Streptococcus pneumoniae fitness and virulence [48].
The higher levels of glutamic acid in the plasma in patients relative
to controls in our study may indicate cellular injury and
protection. Additionally, excess circulation of glutamic acid during
the disease state requires special attention in this particular human
population as it can be associated with central nervous system
damage, which is sometimes associated with severe pneumonia
[49]. L-tryptophan, on the other hand, was lower in plasma of
patients relative to controls. Tryptophan starvation is a recognized
antimicrobial defense mechanism through Indoleamine 2,3-
dioxygenase (IDO) and mediates immunoregulatory effects [50].
It is possible therefore, that tryptophan starvation initially exhibits
an antimicrobial effect to aid in fighting the disease status and later
contributes in regulating the T-cell response from a possible
overstimulation [50]. Urinary L-histidine was also lower in
patients relative to controls. L-histidine is a precursor for the
synthesis of histamine, a major contributor to inflammation,
asthma, and potentially pneumonia in both human [51] and
animal studies [52]. The lack on detection of histamine in urines of
pneumonia patients and retention of L-histidine is possible
indication that histidine is being converted to histamine in the
tissues of pneumonia patients and contributing to their inflamma-
tory state and propagation of disease status.
The sex dependent clustering of the pneumonia group, which
was not present in the controls, points to differences in the
metabolic response to pneumonia between male and female
patients. Sex differences have been documented in survival
following community-acquired pneumonia and nosocomial infec-
tions, which could be explained by differences in immune
responses, genetics, or sex hormone levels [53,54]. Additionally,
a study by Casimir et al on childhood pneumonia revealed
significant differences in inflammatory markers between male and
female patients [55], making identification of metabolic differences
between male and female patients an attractive candidate for
future studies on diagnosis and drug development.
This small-scale preliminary study has clear limitations. It is not
possible to say whether the metabolomic profile seen in these
children with severe pneumonia is pneumonia-specific or associ-
ated with a wider spectrum of illness. Either of these possibilities is
potentially diagnostically significant, and further work investigat-
ing the specificity of the findings must be done to resolve this
question. The literature reporting metabolomic analysis in
infectious diseases is limited. The majority of the work has been
conducted in meningitis patients and considerable work has been
conducted on the assessment of global metabolic profiling of
bacteria [56–58]. Pneumonia specific urinary metabolomic studies
have concentrated on primarily adult populations with specific
aetiology; however, this study is the first to provide pneumonia
metabolomic analysis in urine and plasma from a specific pediatric
population in parallel. Additionally, the differences in markers
identified could be attributed to age and population related
differences, overall aetiology of the pneumonia phenotype, and
technologies and analytical methods utilized. This study was too
small to define organism-specific metabolic responses, which will
be useful for diagnosis, and it was not possible using available
sensitive molecular techniques to distinguish causative pathogens
from asymptomatic ‘DNAemia’. This is a general challenge for the
growing field of molecular diagnostics rather than a limitation of
this study in particular. The size of this study also means it has
likely failed to identify other metabolites that will be important for
diagnostics in the future.
The ability of the methods used in this study to clearly
distinguish the children with severe pneumonia from their controls
points to the considerable potential of metabolomics to improve
diagnosis in sick children and to advance the knowledge of disease
mechanisms. This preliminary work’s importance is further
emphasized by the fact that specific markers were identified in
an outbred human population with genetic variability, no clear
common causative agent, and simply a shared clinical syndrome.
Metabolomics may provide an effective means to overcome the
inability of current molecular pathogen detection techniques to
distinguish causative pathogens from organisms that are ‘innocent
bystanders’. Larger scale studies are now needed to determine the
extent of its potential and to identify markers for different
causative agents and for other potentially important aspects of
disease such as illness severity, key comorbidities, and response to
treatment. Once a panel of key biomarkers has been established
there is the potential to take metabolomics closer to the bedside
through its incorporation into point-of-care devices, which it is
hoped will deliver breakthroughs in care in high mortality settings,
and the evolution of which will likely be rapid in the next few
years.
Supporting Information
Figure S1 Scores plots generated through the chemometric
software SIMCA-P+ vs 12.0. A and B depict the separation
between the controls and pneumonia groups when assessing the
metabolic profile of urines under positive ionization mode. A is a
plot generated from PLS-DA analysis whereas B is an OPLS plot,
from which we are able to determine that a greater variability
exists within the pneumonia group, possibly due to different
aetiological agents. C, D, and E panels in order represent the
PCA, PLS-DA and OPLS plots of the negative ionization mode
urines.
Found at: doi:10.1371/journal.pone.0012655.s001 (0.36 MB
TIF)
Figure S2 Scores plots generated through SIMCA-P+ based on
the metabolic profiles of plasma samples from controls and
pneumonia patients. A, B, and C panels show the PCA, PLS-DA
and OPLS scores plots from positive ionization mode plasma
samples, respectively. D and E show the PLS-DA and OPLS
scores plots from the negative ionization mode.
Found at: doi:10.1371/journal.pone.0012655.s002 (0.37 MB TIF)
Figure S3 PLS-DA scores plots examining the existence of sex
differences based on metabolic profiles between control and
pneumonia groups. Panels A (ESI+) and B (ESI-) based on urinary
metabolic profiles clearly depict that possible differences based on
sex could exist in the pneumonia group. In panels C (ESI+)o f
plasma samples separation of profiles based on sex is still evident,
whereas in panel D (ESI-) of plasma samples the separation is not
existent.
Found at: doi:10.1371/journal.pone.0012655.s003 (0.38 MB TIF)
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